Approximately 80% of patients with advanced or metastatic pancreatic cancer (PC) suffer from an extremely poor prognosis, and the diagnosis of PC is generally at an advanced stage, which also presents a major challenge for clinical treatment, especially when the tumor has metastasized to other organs and proliferated to the extent that adequate surgical resection cannot be performed. Therefore, accurate PC diagnosis and treatment strategies are urgently needed in the early developmental stage. Due to its limited specificity, carbohydrate antigen 19-9 (CA19-9) is generally not recommended for early screening of PC. As the discovery of new serum biomarkers has recently received more attention, its combined detection of PC with CA19-9 has also been explored. Liquid biopsies, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs, and exosomes in blood, as well as biomarkers in urine and saliva, have been increasingly used in PC diagnosis. In addition, new technologies including radiomics, and the generation of mineable high-throughput data from medical images, have also provided a deeper understanding of pancreatic tissue heterogeneity, which holds great promise for the early diagnosis of PC.
This research topic aims to highlight the impact of novel circulating biomarkers and radiomics in the early detection of pancreatic cancer. We are also interested in advances in new therapeutic strategies for pancreatic cancer, including immunotherapy, cell therapy, gene therapy, nanomedicine, etc. We welcome submissions of Original Research, Review, Mini Review, Opinion and Systematic Review covering, but not limited to, the following:
• Novel circulating biomarkers in the early detection of pancreatic cancer
• Radiomics in early detection of pancreatic cancer
• Advances in new therapeutic strategies toward pancreatic cancer, including immunotherapy, cell therapy, gene therapy and nanomedicine, etc.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Approximately 80% of patients with advanced or metastatic pancreatic cancer (PC) suffer from an extremely poor prognosis, and the diagnosis of PC is generally at an advanced stage, which also presents a major challenge for clinical treatment, especially when the tumor has metastasized to other organs and proliferated to the extent that adequate surgical resection cannot be performed. Therefore, accurate PC diagnosis and treatment strategies are urgently needed in the early developmental stage. Due to its limited specificity, carbohydrate antigen 19-9 (CA19-9) is generally not recommended for early screening of PC. As the discovery of new serum biomarkers has recently received more attention, its combined detection of PC with CA19-9 has also been explored. Liquid biopsies, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs, and exosomes in blood, as well as biomarkers in urine and saliva, have been increasingly used in PC diagnosis. In addition, new technologies including radiomics, and the generation of mineable high-throughput data from medical images, have also provided a deeper understanding of pancreatic tissue heterogeneity, which holds great promise for the early diagnosis of PC.
This research topic aims to highlight the impact of novel circulating biomarkers and radiomics in the early detection of pancreatic cancer. We are also interested in advances in new therapeutic strategies for pancreatic cancer, including immunotherapy, cell therapy, gene therapy, nanomedicine, etc. We welcome submissions of Original Research, Review, Mini Review, Opinion and Systematic Review covering, but not limited to, the following:
• Novel circulating biomarkers in the early detection of pancreatic cancer
• Radiomics in early detection of pancreatic cancer
• Advances in new therapeutic strategies toward pancreatic cancer, including immunotherapy, cell therapy, gene therapy and nanomedicine, etc.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
